{
  "name" : "dacemirror.sci-hub.se_journal-article_17bfece2ec715b58a7234b61c8f5d921_shin2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Foxp3 plasmid-encapsulated PLGA nanoparticles attenuate pain behavior in rats with spinal nerve ligation",
    "authors" : [ "Juhee Shin", "Yuhua Yin", "Do Kyung Kim", "Sun Yeul Lee", "Wonhyung Lee", "Joon Won Kang", "Dong Woon Kim", "Jinpyo Hong" ],
    "emails" : [ "visnu528@cnu.ac.kr", "biohjp@cnu.ac.kr" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Microglia play a critical role in neuropathic pain. Since upregulated Foxp3 in microglia enhances tissue repair by resolving neuroinflammation in excitotoxin-induced neuronal death, it may attenuate neuropathic pain in a similar manner. Therefore, this study tests whether Foxp3 introduced with poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles (Foxp3 NPs) can alleviate neuropathic pain by inhibiting microglia activity. The prepared Foxp3 NPs had an anti-inflammatory effect on lipopolysaccharide-stimulated BV2 cells in vitro, and localized to spinal microglia in vivo. Further, the Foxp3 NPs significantly attenuated pain behavior induced by spinal nerve ligation in rats for 7 days by suppressing microglial activity, followed by the downregulation of pro-nociceptive genes and the upregulation of antinociceptive genes in the spinal dorsal horn. Collectively, these data suggest that Foxp3 NPs effectively relieve neuropathic pain in animals by reducing microglia activity and subsequent modulation of neuroinflammation, and may be of therapeutic value in the treatment of neuropathic pain. © 2019 Elsevier Inc. All rights reserved.\nKey words: Neuropathic pain; Foxp3; PLGA nanoparticles; Microglia; Spinal nerve ligation"
    }, {
      "heading" : "Background",
      "text" : "Neuropathic pain can develop in both the peripheral (peripheral sensitization) and central (central sensitization) nervous systems.1 Usually, when peripheral nerves are injured by physical and/or inflammatory stress, several neurotransmit-\nConflicts of interest statement: The authors have no conflict of interest to declare.\nFunding: This research was supported by the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2016M3C7A1905074, 2016R1A2B4009409, 2017R1D1A1B03028839, 2017R1A1A1A05001310).\n⁎Corresponding authors at: 266, Munhwa-ro, Jung-gu, Daejeon, 35015, Republic of Korea.\nE-mail addresses: visnu528@cnu.ac.kr (D.W. Kim), biohjp@cnu.ac.kr (J. Hong).\nhttps://doi.org/10.1016/j.nano.2019.02.023 1549-9634/© 2019 Elsevier Inc. All rights reserved.\nters, including glutamate, ATP, fractalkine and substance P, are released from the presynaptic terminals of the primary afferent neurons of dorsal root ganglia projecting into the dorsal horn of the spinal cord.2 Subsequently, these molecules bind to postsynaptic neuron receptors in the spinal dorsal horn, transmitting nociceptive pain to the brain via the spino-thalamic pathway.3 The molecules can also bind to receptors on the glia of the spinal dorsal horn, inducing the release of diverse molecules and modulating neuron–glia communication in the spinal cord.4 Ultimately, neuropathic pain may be initiated and sustained by the interaction between neurons and the enclosing glia. In particular, activated microglia of the spinal dorsal horn release a variety of cytokines and other factors, such as tumor necrosis factor-alpha (TNF)-α, interleukin (IL)-1β, IL-6, nitric oxide (NO), ATP and prostaglandins, thereby retuning the communication between neurons and glia and further aggravating pain symptoms.5,6\nThe communication between neurons and microglia in neurological disorders has been well studied.7 In the healthy central nervous system (CNS), neurons suppress microglial activation in several ways1: contact-dependent inhibition through the CD200-CD200 receptor (CD200R), HSP60TREM2/DAP12, CD22-CD45 and CD47-CD172A2; cytokine or soluble adhesion molecule-mediated inhibition through soluble intercellular adhesion molecule 5 (ICAM5)-lymphocyte function associated antigen 1 (LFA1), CX3CL1-CX3CR1, the IL-10-IL-10 receptor and transforming growth factor-β (TGFβ)-TGF-β receptor3; neurotransmission-associated inhibition through dopamine receptors (D1, D2, D3 and D4 subtypes) and noradrenaline-adrenoceptors; and4 neuronal electrical activity-mediated inhibition.8 In the diseased or neuronally damaged CNS, however, disruption of these interactions may stimulate microglia and lead to the secretion of several unfavorable factors, thereby accelerating the deterioration caused by these diseases. Therefore, if these interactions and/or their signaling cascades could be artificially re-established via the treatment and/or expression of these molecules, disease progression could be prevented or delayed to some extent. For example, an intrathecal application of CD200 fusion proteins reduced mechanical hypersensitivity in rats with neuropathic pain due to chronic constriction injury, via the attenuation of glial activity and the modulation of inflammatory mediators.9 We also found that Foxp3, downstream of the CD200-CD200R interaction, increased in the microglia of the hippocampus activated by excitotoxins, and shifted pro-inflammatory microglia into anti-inflammatory microglia, thereby accelerating tissue repair and the resolution of neuroinflammation.10 Further, when CD200 fusion proteins were introduced to the rats' primary microglial cells, they greatly stimulated Foxp3 and subsequent arginase 1 (Arg1) expression. In contrast, the CD200 fusion proteins caused no change to Foxp3 expression in CD200Rsilenced cells.10 Therefore, the targeting of Foxp3 may be a useful method for treating neuroinflammatory diseases and neuropathic pain.\nThe two most common approaches in gene-targeting genetic therapy are promoting gene expression or gene silencing. For example, in patients with lipoprotein lipase deficiency, altering the expression of the lipoprotein lipase gene in skeletal muscle, mediated by adeno-associated virus (AAV), was approved by the European Medicines Agency.11 In addition, for the treatment of adult patients with peripheral nerve disease (polyneuropathy) caused by the rare hereditary disease transthyretin-mediated amyloidosis, a small interfering RNA (siRNA)-based gene therapy was recently approved by the US Food and Drug Administration (FDA).12 In this study, we adopted poly (D, Llactic-co-glycolic acid) (PLGA) polymers, instead of viral or classical non-viral mediators, as a therapeutic device to deliver nucleic acids to spinal cells, since the use of PLGA polymers offered several advantages, including reduced cost, and increased safety and ease of use. Additionally, PLGA nanoparticles (NPs) were more selectively absorbed by the spinal microglia of rats with SNL-induced neuropathic pain.13 Thus, in this study, we applied Foxp3 plasmid (pFoxp3)-encapsulated PLGANPs (Foxp3 NPs) to SNL-induced rats for the treatment of neuropathic pain.\nTo test our hypothesis, we investigated whether Foxp3 NPs could reduce pain behavior in rats with SNL-induced neuropathic pain. We found that Foxp3 NPs significantly attenuated pain behavior for 7 days following an intrathecal injection of Foxp3 NPs, due to the decrease of microglial activity. The pain reduction associatedwith Foxp3NPsmay have also beenmediated by a decrease in pro-inflammatory genes, such as TNF-α, IL-1β, IL-6, cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS), and an increase in anti-inflammatory genes, such as IL-10 and Arg1, in the dorsal horn of the spinal cord."
    }, {
      "heading" : "Methods",
      "text" : ""
    }, {
      "heading" : "Animals",
      "text" : "Sprague-Dawley rats (6-week-old males, 150-200 g) were obtained from Daehan Bio Link (DBL, Chung-buk, Republic of Korea) and adapted to the study habitat for 1 week prior to our experiment. Three rats per cage were housed in a controlled environment with 12-h light/dark cycles and free access to food and water. This experiment was approved by the Animal Care and Use Committee at the Chungnam National University (CNUH-018A0020) and followed the ethical guidelines of the National Institutes of Health and the International Association for the Study of Pain.14\nNeuropathic painmodel, pain behavior test, and intrathecal injection\nNeuropathic pain in the spinal nerve roots of rats, as induced by the ligation of lumbar 5 (L5), was the pain model used in this study.3,15 Rats were placed under brief isoflurane anesthesia (2% in oxygen; Hana Pharm, Kyung-gi, Republic of Korea) in a prone position. The paraspinal muscles on the left side were separated using a 2-cm long skin incision. After removal of the L6 transverse process to expose the L4 and L5 vertebrae, the L5 spinal nerve was carefully isolated from the L4 nerve, without injury, and ligated three times using a 3-0 silk thread (Ethicon, Diegem, Belgium). Complete hemostasis was confirmed and the wound was sutured. In the sham group, surgical procedures were the same as those in the SNL group except that the L5 spinal nerve was not ligated. Pain behavior test16 and intrathecal injection17 were precisely described in supplementary materials."
    }, {
      "heading" : "Plasmid construction",
      "text" : "RT-PCR was used to obtain the coding sequence of the mouse Foxp3 gene from the cDNA of primary cultured microglia using a primer pair adapted with the EcoRI or XbaI restriction enzyme sequence (5′-GAA TTC ATG CCC AAC CCT AGG CCA G-3′; 5′-GTCTAGAAGGGCAGGGATTGGAGCACTTG-3′), and then subcloned into a pAAV-EF1a-MCS-T2A-mCherry (pNC) plasmid to achieve the pAAV-EF1a-mFoxp3-T2A-mCherry (pFoxp3) plasmid expressing both mFoxp3 and mCherry. The clone was confirmed by restriction enzyme digestion and sequencing analysis (Cosmogenetech). The pNC was used as the negative control.\nPreparation of plasmid-encapsulated PLGA nanoparticles\nPlasmid-encapsulated PLGA NPs were prepared with minor modifications, as reported previously.13 To produce plasmid-\nencapsulated PLGA NPs, 100 μg of plasmid in 200 μL of TE 8.0 buffer was added in drops to 1.0 ml of dichloromethane (DCM) containing 20 mg of PLGA (Resomer® RG 502H; SigmaAldrich) and emulsified by sonication (50 W, 1 min; VibraCell™ VCX 130; Sonics, Newtown, CT, USA) into a primary W1/O emulsion. Later, 2 mL of 1% PVA1500 (w/v; Thermo Fisher Scientific) was added directly into the primary emulsion and further emulsified by sonication for 1 min to form a W1/O/ W2 double emulsion. The resulting product was then diluted with 6 mL of 1% PVA1500 (w/v) and stirred magnetically for 3 h at room temperature to evaporate the DCM in a fume hood. Finally, the PLGA NPs were collected by centrifugation (Hanil Scientific Inc., Daejeon, Republic of Korea) at 15,000 ×g for 15 min at 4 °C, washed twice with deionized water and freeze-dried. The size and zeta potential of the prepared PLGA NPs were analyzed using the Zetasizer Nano ZS (Malvern Instruments, Malvern, UK), and the diameter and shape were evaluated using scanning electron microscopy (SEM; SNE-4500 M; SEC Co., Ltd., Suwon, Republic of Korea)."
    }, {
      "heading" : "Statistical analysis",
      "text" : "The data are expressed as mean ± standard error of the mean (SEM). Differences among multiple groups were determined by one- or two-way analysis of variance (ANOVA) followed by an appropriate multiple comparison test. Between-group analyses were accomplished using unpaired Student's t tests. P values 0.05 were considered statistically significant. All statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA).\nThe detailed experimental methods of Quantitative real-time PCR18, Immunohistochemistry10, Immunoblot13, and Cytotoxicity assay13 are provided in supplementary materials."
    }, {
      "heading" : "Results",
      "text" : "Foxp3 expression was upregulated in rats with spinal nerve ligation-induced neuropathic pain\nIn a previous report, we showed that, in a kainic, acid-induced neurodegenerative model of mice, upregulation of Foxp3 in the hippocampal microglia promoted tissue repair via decreased neuroinflammation.10 Therefore, we hypothesized that upregulated Foxp3 could attenuate neuropathic pain by reducing microglial activity in a similar way, since microglia play an essential role in the initiation and conservation of pain.\nTo investigate whether Foxp3 is activated during neuropathic pain, we measured the expression of Foxp3 in the dorsal horn of the spinal cord in a rat model of neuropathic pain with spinal nerve ligation (SNL). On days 3 and 7 post-operation, mRNA levels of Foxp3 in the spinal dorsal horn increased significantly in the SNL group compared to the sham group in qPCR analysis (Figure 2, A). Likewise, the number of Foxp3-immunoreactive cells in the spinal dorsal horn also increased in the SNL group (Figure 2, B).\nThese data suggest that SNL-induced neuropathic pain promotes the upregulation of Foxp3 expression in the spinal\ndorsal horn. Therefore, Foxp3 may have a role in the neuropathic pain, and it could be a target to treat neuropathic pain.\nEctopic Foxp3 expression decreased the mRNA levels of proinflammatory genes in LPS-stimulated BV2 cells\nTo prepare the Foxp3 NPs, we first created a pFoxp3 that expressed Foxp3 and mCherry constitutively in cells. The pFoxp3 construct was created by subcloning a coding sequence of mouse Foxp3 (1287 base pair) into a negative control plasmid (pNC) that expressed only mCherry (Figure 3, A, left). The integrity of the pFoxp3 clone was validated by sequencing analysis. In addition, to verify the expression of Foxp3 and mCherry in cells, after pNC or pFoxp3 was transfected into HEK293T cells for 24 h, mCherry expression was certified by the presence of red color under a fluorescent microscope (Figure 3, A, middle). Foxp3 expression was further explored by immunoblot analysis with anti-Foxp3 antibodies (Figure 3, A, right).\nWe then assessed whether Foxp3 could inhibit the gene expression of proinflammatory cytokines in lipopolysaccharide (LPS)-stimulated microglial cells. Following the transfection of pNC or pFoxp3 into BV2 microglia cells for 2 days, the cells were further incubated in the presence of LPS (100 ng/ml) for 3 h, then used in qPCR analysis to assess mRNA levels of proinflammatory genes. Compared to the LPS-treated pNC group, the gene expression levels of proinflammatory cytokines in the LPS-treated pFoxp3 group, such as TNF-α, IL-1β and IL6, significantly declined by 70%, 40% and 76%, respectively.\nThese data indicate that elevated Foxp3 expression efficiently downregulates the transcription of proinflammatory genes, including TNF-α, IL-1β and IL-6, in LPS-stimulated microglia cells.\nPreparation, characterization and cytotoxicity of plasmidencapsulated PLGA nanoparticles\nTo effectively introduce the pFoxp3 into the spinal microglia of rats with neuropathic pain, we considered several factors when selecting the gene delivery system, including efficacy, cost, safety and convenience. We adopted the PLGA copolymer as a vector for gene delivery because it was already proven to be biodegradable and biocompatible in humans by the US FDA.19 We prepared plasmid-incorporated PLGA NPs using the conventional double emulsion (W1/O/W2) method, with brief sonication to trap hydrophilic plasmids in the PLGA polymers.20 When the prepared NPs were characterized with the Zetasizer, the average size and zeta-potential of NPs were 224 ± 16.5 nm and −18.9 ± 5.08 mV, respectively. The integrity and morphology of the NPs were validated by SEM (Figure 4, A).\nFurthermore, although the safety of PLGA was previously confirmed in vivo, it was necessary to examine the cytotoxicity of plasmid-encapsulated PLGA NPs because their safety had not been tested previously. Thus, when a series of NP concentrations (0-200 μg/ml) were treated to BV2 cells for 24 h, they had little influence on cell death according to MTT assay (Figure 4, B).\nFoxp3 NPs suppressed the transcription of proinflammatory mediators in LPS-stimulated BV2 cells\nPrior to the application of Foxp3 NPs to the SNL-induced rats, we verified in vitro whether cells could uptake Foxp3 NPs,\nexpress Foxp3 protein or promote anti-inflammatory activity against LPS stimulation. To reveal the gene expression in the NP-treated cells, mCherry and Foxp3 expression levels were examined by fluorescence microscopy (left) and western blot analysis (right), after HEK293T cells were incubated with NC or Foxp3 NPs for 48 h (Figure 5, A).\nMoreover, we explored whether Foxp3 NPs could prohibit the mRNA expression of proinflammatory genes in the LPSactivated microglial cells. After BV2 cells were treated with NC or Foxp3 NPs for 2 days, the cells were further incubated with LPS (100 ng/ml) for 3 h. The mRNA levels of proinflammatory genes, such as TNF-α, IL-1β and IL-6, markedly increased in the NC NP-treated cells. However, the transcriptional levels of proinflammatory genes significantly decreased, by 60-81%, in the Foxp3 NP-treated cells (Figure 5, B).\nCollectively, these data suggest that BV2 microglial cells intake prepared Foxp3 NPs and sufficiently express Foxp3 protein, thereby markedly downregulating the gene expression of proinflammatory mediators, including TNF-α, IL-1β and IL-6, in LPS-inflamed BV2 cells.\nFoxp3 NPs are predominantly incorporated to spinal microglia of SNL-induced rats\nBefore the in vivo application of the Foxp3 NPs to rats with neuropathic pain, we determined that the Foxp3 NPs preferentially localized to spinal microglia and expressed Foxp3 at the cellular level in SNL-induced rats, where Foxp3 has an antiinflammatory effect on the microglia.10 Thus, to observe Foxp3 NP-mediated Foxp3 expression in the spinal cord, we administered Foxp3 NPs to the SNL-induced rats via intrathecal injection. On day 4 post-injection, L5 spinal sections were immuno-stained with anti-Foxp3 antibodies. Consequently, Foxp3 was co-expressed with mCherry in the spinal cells\nincorporated with the Foxp3 NPs (Figure 6, A). To determine which types of cells could predominantly intake the Foxp3 NPs in the spinal cord of SNL-induced rats, the L5 spinal sections used in this study were incubated with cell-type specific markers, including Iba1 (microglia), GFAP (astrocytes), and NeuN (neurons). According to the mCherry and marker characterizations, the Foxp3 NPs were largely absorbed into the spinal cord microglia, but not into the spinal cord astrocytes and neurons (Figure 6, B). Ultimately, these data show that Foxp3 NPs mainly localize the spinal microglia in SNL-induced rats, and successfully promote Foxp3 expression in microglial cells.\nFoxp3 NPs attenuated pain behavior in rats with SNL by reducing microglial activity\nTo investigate the analgesic effect of Foxp3 NPs on neuropathic pain, it was necessary to establish an animal model of neuropathic pain. In this study, we adopted an SNL rat model due to its ease of use and reproducibility, as shown in previous animal studies.15 Rats insensitive to von Frey filaments (N 10 g) were identified and underwent SNL surgery. Von Frey filament tests were then performed on days 3, 5, 7, 10 and 14 post-surgery. Neuropathic pain was induced on day 3 and lasted on the ipsilateral side of the hind paws of rats with SNL (Supplementary Figure 1, A).\nAs there are numerous reports of spinal microglia being noticeably activated in the ipsilateral dorsal horn of the spinal cord, L5 spinal sections from SNL-induced rats were immunostained with anti-Iba1 antibodies, a specific marker of microglia, on day 7 post-surgery21. In a similar manner to previous reports, microglia activation greatly increased on the ipsilateral side of the spinal dorsal horn in rats with SNL compared to the contralateral side (Supplementary Figure 1, B).\nTo verify whether Foxp3 NPs have an analgesic effect on neuropathic pain, we introduced the Foxp3 NPs into the L5/L6 intervertebral space of rats with SNL-induced neuropathic pain. On day 3 post-SNL surgery, NC or Foxp3 NPs were administered intrathecally to rats with von Frey filament sensitivity (b2.0 g). The mechanical pain thresholds of the rats were measured by daily application of von Frey filaments on days 5-10 post-surgery. Mechanical hypersensitivity was decreased for approximately 7 days in the Foxp3 NP-treated\ngroup, especially on day 4 post-injection, while no change was seen at any time in the NC NPs-treated group (Figure 7, A).\nA previous study showed that elevated Foxp3 expression increases neuronal survival by reducing microglial activity in kainic acid-induced hippocampal neuronal cell death.10 Hence, we investigated whether or not the reduction of neuropathic pain seen in our study was attributable to the decrease of microglial activity in the spinal dorsal horn produced by the administration of Foxp3 NPs. On day 4 post-NP injection, the Iba1 reactivity of\nmicroglia in the Foxp3 NPs-treated group decreased significantly, by 42.3%, compared to the NC NPs-treated group (Figure 7, B).\nThe results of our study indicate that, by lowering microglial activity, Foxp3 NPs attenuate pain behavior for 7 days in rats with SNL-induced neuropathic pain.\nFoxp3 NPs modulated the expression of neuropathic painrelated genes in the spinal dorsal horn of SNL-induced rats\nTo understand the mechanism of pain attenuation by Foxp3 NPs, we investigated the levels of pro- and anti-nociceptive mediators in the ipsilateral dorsal horn of the spinal cord, because activated microglia modulate the expression of these inflammatory factors during neuropathic pain.22 On day 3 post-SNL surgery, NC or Foxp3 NPs were intrathecally injected into rats with SNL-induced neuropathic pain. After 4 days, the mRNA levels of inflammatory genes were measured by qPCR. The mRNA levels of proinflammatory genes, such as TNF-α, IL-1β, IL-6 andCOX-2, decreased by 61%-83% in the Foxp3NPs-treated group compared to the NC NPs-treated group. In contrast, the mRNA level of the anti-inflammatory genes, including IL-10,\nincreased by 2.71-fold in the Foxp3 NPs-treated group compared to the NC NPs-treated group (Figure 8, A).\nOn day 4 post-injection of NC or Foxp3 NPs, L5 spinal tissues were incubated with anti-Iba1 and anti-iNOS (proinflammatory markers) or anti-Arg1 (anti-inflammatory markers) antibodies to investigate whether or not Foxp3 NPs modulate the expression of these neuropathic pain-related genes in spinal microglia.10,22 The expression of iNOS and Arg1 in the ipsilateral dorsal horn of the spinal cord clearly increased in the NC NPs-treated group with SNL compared to the sham group (Figure 8, B). However, while iNOS was downregulated by 37.6% in the Foxp3 NPs-treated group, Arg1 was upregulated by 70.3% compared to the NC NPs-treated group (Figure 7, B). As expected, in accordance with double-immunostaining analysis with anti-Iba1 antibodies, these changes mainly occurred in the spinal microglia of the Foxp3 NPs-treated group (Figure 8, B).\nThese data indicate that Foxp3 NPs relieve SNL-induced neuropathic pain in rats by the downregulation of proinflammatory genes, such as TNF-α, IL-1β, IL-6, COX-2 and iNOS, and the upregulation of anti-inflammatory genes, such as IL-10 and Arg1, in the spinal dorsal horn."
    }, {
      "heading" : "Discussion",
      "text" : "In this study, we developed a new analgesic based on the understanding that certain causes of neuropathic pain may also aid in its treatment. In our previous study, upregulated Foxp3\nexpression in microglia enhanced tissue repair by reducing the neuroinflammation induced by neurotoxins.10 Thus, we reasoned that Foxp3 could reduce neuropathic pain in a similar manner, as microglia play a critical role in neuropathic pain. When Foxp3 was overexpressed on the spinal microglia of SNL-\ninduced rats with Foxp3 NPs, their pain behavior was obviously attenuated for 7 days by deactivation of the microglia, followed by downregulation of proinflammatory mediators, including TNF-α, IL-1β, IL-6, COX-2 and iNOS, and upregulation of antiproinflammatory genes, such as IL-10 and Arg1, in the spinal dorsal horn (Figure 1).\nTo treat patients experiencing neuropathic pain, several kinds of drugs, including non-steroidal anti-inflammatory drugs, ion channel blockers, selective serotonin reuptake inhibitors and opioids, are typically prescribed.23 When these drugs are ineffective, additional therapies, including nerve block, spinal cord stimulation, and deep brain stimulation, are also typically applied to mitigate pain.24,25 These approaches are limited, however, due to the different etiologies of neuropathic pain.26 Therefore, new analgesics based on knowledge of the biological mechanisms of pain are necessary to overcome these limitations. Scientists continue to explore new and improved medications that address neuropathic pain in animal models, including several gene therapies using siRNA, clustered regularly interspaced palindromic repeats (CRISPR) and viruses.\nSince activated microglia are deeply involved in the development and maintenance of neuropathic pain, the reduction of microglial activity could improve pain conditions. Microglial inactivators, such as minocycline, pentoxifylline and ibudilast, apparently attenuate neuropathic pain.27 Unfortunately, due to their short half-life, these compounds only provide analgesia for a limited time.28 To address this problem, some neuroscientists have shifted their focus from chemical inhibitors to neuropathic pain-\nrelated genes, because the analgesic effect of gene therapy is proving to be much more persistent than that of chemical therapy.\nIn our previous research, because the phosphorylation of p38 in spinal microglia was shown to be the key signaling pathway in the development of neuropathic pain, p38 siRNA-loaded PLGA NPs were introduced into the intrathecal space of rats with SNLinduced neuropathic pain to silence the p38 gene in the spinal microglia. Consequently, mechanical allodynia was significantly reduced for 5 days by the silencing of the p38 gene and subsequent downregulation of spinal microglial activity.13 In the present study, we attempted to enhance the symptoms of neuropathic pain by decreasing microglial activity via upregulation of the Foxp3 gene, an anti-inflammatory factor in the microglia. Foxp3 was initially identified as a specific marker for CD4+ and CD25+ Treg cells, and was later found in other cells, including microglia.29 Interestingly, upregulation of Foxp3 reduced neuronal death in the hippocampus by attenuating neuroinflammation and modulating the expression of inflammatory genes, such as Arg1 and iNOS, in a kainic-induced mouse model of neurodegeneration.10 Thus, to investigate whether Foxp3 could similarly attenuate neuropathic pain owing to its anti-inflammatory effect on microglia, we introduced pFoxp3 into the spinal microglia of SNL-induced rats with the aid of pFoxp3-encapsulated PLGA NPs. Prior to the formulation of Foxp3 NPs, a Foxp3 gene-encoded clone was prepared and evaluated by qPCR for its anti-inflammatory effect on LPSstimulated BV2 cells. The synthesized Foxp3 NPs were then assessed in terms of their non-cytotoxicity and anti-inflammatory\neffects on LPS-activated BV2 cells in vitro, while the expression of Foxp3 in spinal microglia was verified in vivo. Finally, we revealed that Foxp3 NPs attenuated mechanical allodynia during von Frey filament tests, as shown by decreased microglial activation, followed by the modulation of neuroinflammationrelated genes: the downregulation of pro-inflammatory genes, such as TNF-α, IL-1β, IL-6 and iNOS, and the upregulation of anti-inflammatory genes, such as IL-10, and Arg1. These findings are consistent with previous studies demonstrating suppression of microglial activity via anti-inflammatory genes, such as IL-10, thereby ameliorating pain behavior by tuning neuroinflammatory genes that are pro- or anti-nociceptive.30\nIn this study, the PLGA co-polymer was employed in several ways in vivo to deliver pFoxp3. The PLGA co-polymer is a wellknown, safe and biodegradable biomaterial approved by the US FDA.12 Furthermore, the prepared PLGA NPs (224 nm in diameter) were large enough to enclose most of the plasmid (100 μg per 25 mg PLGA), while also readily endocytosing into the microglia. Furthermore, although our study showed that the PLGA NPs were predominantly localized to microglia, future studies may improve the microglia specificity of PLGA NPs via the conjugation of microglia-specific CX3CL1 and CD200 peptide fragments.\nIn conclusion, our data indicate that Foxp3 NPs effectively alleviate SNL-induced neuropathic pain in rats by decreasing microglial activity and regulating the gene expression of neuropathic pain-related pro- and anti-inflammatory mediators. Therefore, Foxp3 NPs may constitute a new and revolutionary therapy for the treatment of neuropathic pain patients."
    }, {
      "heading" : "Acknowledgments",
      "text" : "Not applicable."
    }, {
      "heading" : "Authors’ Contribution",
      "text" : "JS and YY took part in the design of the study, the experiments of pain behavior, immunoblotting immunostaining, PCR, the data analysis, and the preparation of drafted manuscript. DKK and JH carried out plasmid construction, nanoparticles preparation and data analysis. SYL, WL and JWK participated in the design of the study and data analysis. JH, DWK and JH carried out the design of the study and data analysis, and wrote the manuscript. All authors read and approved the final manuscript."
    }, {
      "heading" : "Appendix A. Supplementary data",
      "text" : "Supplementary data to this article can be found online at https://doi.org/10.1016/j.nano.2019.02.023."
    } ],
    "references" : [ {
      "title" : "Neurotrauma and inflammation: CNS and PNS responses. Mediators Inflamm 2015;2015251204",
      "author" : [ "BS Mietto", "K Mostacada", "AM. Martinez" ],
      "venue" : null,
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2015
    }, {
      "title" : "Peripheral sensitization of sensory neurons",
      "author" : [ "Chaban VV" ],
      "venue" : "Ethn Dis 2010;20:S1-3-6",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2010
    }, {
      "title" : "Galectin-3 inhibition is associated with neuropathic pain attenuation after peripheral nerve injury",
      "author" : [ "Z Ma", "Q Han", "X Wang", "Z Ai", "Y. Zheng" ],
      "venue" : "PLoS One 2016;11e0148792",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2016
    }, {
      "title" : "Rats as indicators of the presence and dispersal of six zoonotic microbial agents in Cyprus, an island ecosystem: a seroepidemiological study",
      "author" : [ "A Psaroulaki", "M Antoniou", "P Toumazos", "A Mazeris", "I Ioannou", "D Chochlakis" ],
      "venue" : "Soc Trop Med Hyg 2010;104:733-9",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2010
    }, {
      "title" : "The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines",
      "author" : [ "PJ Austin", "G. Moalem-Taylor" ],
      "venue" : "J Neuroimmunol",
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2010
    }, {
      "title" : "Role of the immune system in chronic pain",
      "author" : [ "F Marchand", "M Perretti", "SB. McMahon" ],
      "venue" : "Nat Rev Neurosci",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2005
    }, {
      "title" : "Downregulation of spinal astrocytic connexin43 leads to upregulation of interleukin-6 and cyclooxygenase-2 and mechanical hypersensitivity in mice",
      "author" : [ "N Morioka", "S Fujii", "S Kondo", "FF Zhang", "K Miyauchi", "Y Nakamura" ],
      "venue" : "Glia",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2018
    }, {
      "title" : "The myeloid cells of the central nervous system parenchyma",
      "author" : [ "Ransohoff RM", "Cardona AE" ],
      "venue" : "Nature",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2010
    }, {
      "title" : "CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model",
      "author" : [ "HernangomezM", "I Klusakova", "JoukalM", "I Hradilova-Svizenska", "C Guaza", "P. Dubovy" ],
      "venue" : "J Neuroinflammation",
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2016
    }, {
      "title" : "CD200R/Foxp3mediated signalling regulates microglial activation",
      "author" : [ "MH Yi", "E Zhang", "JJ Kim", "H Baek", "N Shin", "S Kim" ],
      "venue" : null,
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2016
    }, {
      "title" : "From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world",
      "author" : [ "JJ Kastelein", "CJ Ross", "MR. Hayden" ],
      "venue" : "Hum Gene Ther 2013;24:472-8",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2013
    }, {
      "title" : "Gene-silencing technology gets first drug approval after 20year wait",
      "author" : [ "H. Ledford" ],
      "venue" : "Nature",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2018
    }, {
      "title" : "p38 siRNAencapsulated PLGA nanoparticles alleviate neuropathic pain behavior in rats by inhibiting microglia activation. Nanomedicine (Lond) 2018;13:1607-21",
      "author" : [ "J Shin", "Y Yin", "H Park", "S Park", "UL Triantafillu", "Y Kim" ],
      "venue" : null,
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2018
    }, {
      "title" : "Expression of LC3 and Beclin 1 in the spinal dorsal horn following spinal nerve ligation-induced neuropathic pain",
      "author" : [ "E Zhang", "MH Yi", "Y Ko", "HW Kim", "JH Seo", "YH Lee" ],
      "venue" : "Brain Res",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2013
    }, {
      "title" : "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat",
      "author" : [ "Kim SH", "Chung JM" ],
      "venue" : null,
      "citeRegEx" : "15",
      "shortCiteRegEx" : "15",
      "year" : 1992
    }, {
      "title" : "Segmental spinal nerve ligation model of neuropathic pain",
      "author" : [ "JM Chung", "HK Kim", "K. Chung" ],
      "venue" : "Methods Mol Med",
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2004
    }, {
      "title" : "Intrathecal morphine in mice: a new technique",
      "author" : [ "Hylden JL", "Wilcox GL" ],
      "venue" : "Pharmacol",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 1980
    }, {
      "title" : "Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain 2008;131:3019-33",
      "author" : [ "IH Cho", "J Hong", "EC Suh", "JH Kim", "H Lee", "JE Lee" ],
      "venue" : null,
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2008
    }, {
      "title" : "Dual-drug containing core-shell nanoparticles for lung cancer therapy",
      "author" : [ "JU Menon", "A Kuriakose", "R Iyer", "E Hernandez", "L Gandee", "S Zhang" ],
      "venue" : null,
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 2017
    }, {
      "title" : "Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.Methods",
      "author" : [ "F Gu", "R Langer", "OC. Farokhzad" ],
      "venue" : "Mol Biol",
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2009
    }, {
      "title" : "p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain",
      "author" : [ "SX Jin", "ZY Zhuang", "CJ Woolf", "RR. Ji" ],
      "venue" : "J Neurosci 2003;23:4017-22",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2003
    }, {
      "title" : "Targeting the microglial signaling pathways: new insights in the modulation of neuropathic pain",
      "author" : [ "K Popiolek-Barczyk", "J. Mika" ],
      "venue" : "Curr Med Chem",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2016
    }, {
      "title" : "Drugs for neuropathic pain",
      "author" : [ "E Kalso", "DJ Aldington", "RA. Moore" ],
      "venue" : "BMJ 2013;347:f7339",
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2013
    }, {
      "title" : "Intranasal ketamine reduces pain of digital nerve block; a double blind randomized clinical trial",
      "author" : [ "A Nejati", "M Jalili", "S Abbasi", "F Talebi Sarwari", "A Bidari", "M Ghajarzadeh" ],
      "venue" : "Emerg Med",
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2018
    }, {
      "title" : "Evaluation of different doses of transcutaneous nerve stimulation for pain relief during labour: a randomized controlled trial",
      "author" : [ "A Baez-Suarez", "E Martin-Castillo", "J Garcia-Andujar", "JA Garcia-Hernandez", "MP Quintana-Montesdeoca", "JF. Loro-Ferrer" ],
      "venue" : "Trials",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2018
    }, {
      "title" : "Spinal cord stimulation for neuropathic pain: current perspectives",
      "author" : [ "T. Wolter" ],
      "venue" : "J Pain Res",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2014
    }, {
      "title" : "Minocycline attenuates stress-induced behavioral changes via its anti-inflammatory effects in an animal model of post-traumatic stress disorder",
      "author" : [ "W Wang", "R Wang", "J Xu", "X Qin", "H Jiang", "A Khalid" ],
      "venue" : "Front Psych 2018;9:558",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2018
    }, {
      "title" : "Paradoxical effect of minocycline on established neuropathic pain in rat",
      "author" : [ "M Zarei", "M Sabetkasaei", "T. Moini-Zanjani" ],
      "venue" : "EXCLI J 2017;16:229-35",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2017
    }, {
      "title" : "Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.Nat Immunol 2003;4:330-6",
      "author" : [ "Fontenot JD", "GavinMA", "RudenskyAY" ],
      "venue" : null,
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 2003
    }, {
      "title" : "Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain",
      "author" : [ "ED Milligan", "RG Soderquist", "SM Malone", "JH Mahoney", "TS Hughes", "SJ Langer" ],
      "venue" : "Neuron Glia Biol",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2006
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Neuropathic pain can develop in both the peripheral (peripheral sensitization) and central (central sensitization) nervous systems.(1) Usually, when peripheral nerves are injured by physical and/or inflammatory stress, several neurotransmit-",
      "startOffset" : 131,
      "endOffset" : 134
    }, {
      "referenceID" : 1,
      "context" : "ters, including glutamate, ATP, fractalkine and substance P, are released from the presynaptic terminals of the primary afferent neurons of dorsal root ganglia projecting into the dorsal horn of the spinal cord.(2) Subsequently, these molecules bind to postsynaptic neuron receptors in the spinal dorsal horn, transmitting nociceptive pain to the brain via the spino-thalamic pathway.",
      "startOffset" : 211,
      "endOffset" : 214
    }, {
      "referenceID" : 2,
      "context" : "Subsequently, these molecules bind to postsynaptic neuron receptors in the spinal dorsal horn, transmitting nociceptive pain to the brain via the spino-thalamic pathway.(3) The molecules can also bind to receptors on the glia of the spinal dorsal horn, inducing the release of diverse molecules and modulating neuron–glia communication in the spinal cord.",
      "startOffset" : 169,
      "endOffset" : 172
    }, {
      "referenceID" : 3,
      "context" : "The molecules can also bind to receptors on the glia of the spinal dorsal horn, inducing the release of diverse molecules and modulating neuron–glia communication in the spinal cord.(4) Ultimately, neuropathic pain may be initiated and sustained by the interaction between neurons and the enclosing glia.",
      "startOffset" : 182,
      "endOffset" : 185
    }, {
      "referenceID" : 4,
      "context" : "In particular, activated microglia of the spinal dorsal horn release a variety of cytokines and other factors, such as tumor necrosis factor-alpha (TNF)-α, interleukin (IL)-1β, IL-6, nitric oxide (NO), ATP and prostaglandins, thereby retuning the communication between neurons and glia and further aggravating pain symptoms.(5,6)",
      "startOffset" : 324,
      "endOffset" : 329
    }, {
      "referenceID" : 5,
      "context" : "In particular, activated microglia of the spinal dorsal horn release a variety of cytokines and other factors, such as tumor necrosis factor-alpha (TNF)-α, interleukin (IL)-1β, IL-6, nitric oxide (NO), ATP and prostaglandins, thereby retuning the communication between neurons and glia and further aggravating pain symptoms.(5,6)",
      "startOffset" : 324,
      "endOffset" : 329
    }, {
      "referenceID" : 6,
      "context" : "The communication between neurons and microglia in neurological disorders has been well studied.(7) In the healthy central nervous system (CNS), neurons suppress microglial activation in several ways(1): contact-dependent inhibition through the CD200-CD200 receptor (CD200R), HSP60TREM2/DAP12, CD22-CD45 and CD47-CD172A(2); cytokine or soluble adhesion molecule-mediated inhibition through soluble intercellular adhesion molecule 5 (ICAM5)-lymphocyte function associated antigen 1 (LFA1), CX3CL1-CX3CR1, the IL-10-IL-10 receptor and transforming growth factor-β (TGFβ)-TGF-β receptor(3); neurotransmission-associated inhibition through dopamine receptors (D1, D2, D3 and D4 subtypes) and noradrenaline-adrenoceptors; and(4) neuronal electrical activity-mediated inhibition.",
      "startOffset" : 96,
      "endOffset" : 99
    }, {
      "referenceID" : 7,
      "context" : "In the healthy central nervous system (CNS), neurons suppress microglial activation in several ways(1): contact-dependent inhibition through the CD200-CD200 receptor (CD200R), HSP60TREM2/DAP12, CD22-CD45 and CD47-CD172A(2); cytokine or soluble adhesion molecule-mediated inhibition through soluble intercellular adhesion molecule 5 (ICAM5)-lymphocyte function associated antigen 1 (LFA1), CX3CL1-CX3CR1, the IL-10-IL-10 receptor and transforming growth factor-β (TGFβ)-TGF-β receptor(3); neurotransmission-associated inhibition through dopamine receptors (D1, D2, D3 and D4 subtypes) and noradrenaline-adrenoceptors; and(4) neuronal electrical activity-mediated inhibition.(8) In the diseased or neuronally damaged CNS, however, disruption of these interactions may stimulate microglia and lead to the secretion of several unfavorable factors, thereby accelerating the deterioration caused by these diseases.",
      "startOffset" : 673,
      "endOffset" : 676
    }, {
      "referenceID" : 8,
      "context" : "For example, an intrathecal application of CD200 fusion proteins reduced mechanical hypersensitivity in rats with neuropathic pain due to chronic constriction injury, via the attenuation of glial activity and the modulation of inflammatory mediators.(9) We also found that Foxp3, downstream of the CD200-CD200R interaction, increased in the microglia of the hippocampus activated by excitotoxins, and shifted pro-inflammatory microglia into anti-inflammatory microglia, thereby accelerating tissue repair and the resolution of neuroinflammation.",
      "startOffset" : 250,
      "endOffset" : 253
    }, {
      "referenceID" : 9,
      "context" : "We also found that Foxp3, downstream of the CD200-CD200R interaction, increased in the microglia of the hippocampus activated by excitotoxins, and shifted pro-inflammatory microglia into anti-inflammatory microglia, thereby accelerating tissue repair and the resolution of neuroinflammation.(10) Further, when CD200 fusion proteins were introduced to the rats' primary microglial cells, they greatly stimulated Foxp3 and subsequent arginase 1 (Arg1) expression.",
      "startOffset" : 291,
      "endOffset" : 295
    }, {
      "referenceID" : 9,
      "context" : "In contrast, the CD200 fusion proteins caused no change to Foxp3 expression in CD200Rsilenced cells.(10) Therefore, the targeting of Foxp3 may be a useful method for treating neuroinflammatory diseases and neuropathic pain.",
      "startOffset" : 100,
      "endOffset" : 104
    }, {
      "referenceID" : 10,
      "context" : "For example, in patients with lipoprotein lipase deficiency, altering the expression of the lipoprotein lipase gene in skeletal muscle, mediated by adeno-associated virus (AAV), was approved by the European Medicines Agency.(11) In addition, for the treatment of adult patients with peripheral nerve disease (polyneuropathy) caused by the rare hereditary disease transthyretin-mediated amyloidosis, a small interfering RNA (siRNA)-based gene therapy was recently approved by the US Food and Drug Administration (FDA).",
      "startOffset" : 224,
      "endOffset" : 228
    }, {
      "referenceID" : 11,
      "context" : "In addition, for the treatment of adult patients with peripheral nerve disease (polyneuropathy) caused by the rare hereditary disease transthyretin-mediated amyloidosis, a small interfering RNA (siRNA)-based gene therapy was recently approved by the US Food and Drug Administration (FDA).(12) In this study, we adopted poly (D, Llactic-co-glycolic acid) (PLGA) polymers, instead of viral or classical non-viral mediators, as a therapeutic device to deliver nucleic acids to spinal cells, since the use of PLGA polymers offered several advantages, including reduced cost, and increased safety and ease of use.",
      "startOffset" : 288,
      "endOffset" : 292
    }, {
      "referenceID" : 12,
      "context" : "Additionally, PLGA nanoparticles (NPs) were more selectively absorbed by the spinal microglia of rats with SNL-induced neuropathic pain.(13) Thus, in this study, we applied Foxp3 plasmid (pFoxp3)-encapsulated PLGANPs (Foxp3 NPs) to SNL-induced rats for the treatment of neuropathic pain.",
      "startOffset" : 136,
      "endOffset" : 140
    }, {
      "referenceID" : 13,
      "context" : "This experiment was approved by the Animal Care and Use Committee at the Chungnam National University (CNUH-018A0020) and followed the ethical guidelines of the National Institutes of Health and the International Association for the Study of Pain.(14)",
      "startOffset" : 247,
      "endOffset" : 251
    }, {
      "referenceID" : 2,
      "context" : "Neuropathic pain in the spinal nerve roots of rats, as induced by the ligation of lumbar 5 (L5), was the pain model used in this study.(3,15) Rats were placed under brief isoflurane anesthesia (2% in oxygen; Hana Pharm, Kyung-gi, Republic of Korea) in a prone position.",
      "startOffset" : 135,
      "endOffset" : 141
    }, {
      "referenceID" : 14,
      "context" : "Neuropathic pain in the spinal nerve roots of rats, as induced by the ligation of lumbar 5 (L5), was the pain model used in this study.(3,15) Rats were placed under brief isoflurane anesthesia (2% in oxygen; Hana Pharm, Kyung-gi, Republic of Korea) in a prone position.",
      "startOffset" : 135,
      "endOffset" : 141
    }, {
      "referenceID" : 12,
      "context" : "Plasmid-encapsulated PLGA NPs were prepared with minor modifications, as reported previously.(13) To produce plasmid-",
      "startOffset" : 93,
      "endOffset" : 97
    }, {
      "referenceID" : 9,
      "context" : "In a previous report, we showed that, in a kainic, acid-induced neurodegenerative model of mice, upregulation of Foxp3 in the hippocampal microglia promoted tissue repair via decreased neuroinflammation.(10) Therefore, we hypothesized that upregulated Foxp3 could attenuate neuropathic pain by reducing microglial activity in a similar way, since microglia play an essential role in the initiation and conservation of pain.",
      "startOffset" : 203,
      "endOffset" : 207
    }, {
      "referenceID" : 18,
      "context" : "We adopted the PLGA copolymer as a vector for gene delivery because it was already proven to be biodegradable and biocompatible in humans by the US FDA.(19) We prepared plasmid-incorporated PLGA NPs using the conventional double emulsion (W1/O/W2) method, with brief sonication to trap hydrophilic plasmids in the PLGA polymers.",
      "startOffset" : 152,
      "endOffset" : 156
    }, {
      "referenceID" : 19,
      "context" : "We prepared plasmid-incorporated PLGA NPs using the conventional double emulsion (W1/O/W2) method, with brief sonication to trap hydrophilic plasmids in the PLGA polymers.(20) When the prepared NPs were characterized with the Zetasizer, the average size and zeta-potential of NPs were 224 ± 16.",
      "startOffset" : 171,
      "endOffset" : 175
    }, {
      "referenceID" : 9,
      "context" : "Before the in vivo application of the Foxp3 NPs to rats with neuropathic pain, we determined that the Foxp3 NPs preferentially localized to spinal microglia and expressed Foxp3 at the cellular level in SNL-induced rats, where Foxp3 has an antiinflammatory effect on the microglia.(10) Thus, to observe Foxp3 NP-mediated Foxp3 expression in the spinal cord, we administered Foxp3 NPs to the SNL-induced rats via intrathecal injection.",
      "startOffset" : 280,
      "endOffset" : 284
    }, {
      "referenceID" : 14,
      "context" : "In this study, we adopted an SNL rat model due to its ease of use and reproducibility, as shown in previous animal studies.(15) Rats insensitive to von Frey filaments (N 10 g) were identified and underwent SNL surgery.",
      "startOffset" : 123,
      "endOffset" : 127
    }, {
      "referenceID" : 9,
      "context" : "A previous study showed that elevated Foxp3 expression increases neuronal survival by reducing microglial activity in kainic acid-induced hippocampal neuronal cell death.(10) Hence, we investigated whether or not the reduction of neuropathic pain seen in our study was attributable to the decrease of microglial activity in the spinal dorsal horn produced by the administration of Foxp3 NPs.",
      "startOffset" : 170,
      "endOffset" : 174
    }, {
      "referenceID" : 21,
      "context" : "To understand the mechanism of pain attenuation by Foxp3 NPs, we investigated the levels of pro- and anti-nociceptive mediators in the ipsilateral dorsal horn of the spinal cord, because activated microglia modulate the expression of these inflammatory factors during neuropathic pain.(22) On day 3 post-SNL surgery, NC or Foxp3 NPs were intrathecally injected into rats with SNL-induced neuropathic pain.",
      "startOffset" : 285,
      "endOffset" : 289
    }, {
      "referenceID" : 9,
      "context" : "On day 4 post-injection of NC or Foxp3 NPs, L5 spinal tissues were incubated with anti-Iba1 and anti-iNOS (proinflammatory markers) or anti-Arg1 (anti-inflammatory markers) antibodies to investigate whether or not Foxp3 NPs modulate the expression of these neuropathic pain-related genes in spinal microglia.(10,22) The expression of iNOS and Arg1 in the ipsilateral dorsal horn of the spinal cord clearly increased in the NC NPs-treated group with SNL compared to the sham group (Figure 8, B).",
      "startOffset" : 308,
      "endOffset" : 315
    }, {
      "referenceID" : 21,
      "context" : "On day 4 post-injection of NC or Foxp3 NPs, L5 spinal tissues were incubated with anti-Iba1 and anti-iNOS (proinflammatory markers) or anti-Arg1 (anti-inflammatory markers) antibodies to investigate whether or not Foxp3 NPs modulate the expression of these neuropathic pain-related genes in spinal microglia.(10,22) The expression of iNOS and Arg1 in the ipsilateral dorsal horn of the spinal cord clearly increased in the NC NPs-treated group with SNL compared to the sham group (Figure 8, B).",
      "startOffset" : 308,
      "endOffset" : 315
    }, {
      "referenceID" : 9,
      "context" : "In our previous study, upregulated Foxp3 expression in microglia enhanced tissue repair by reducing the neuroinflammation induced by neurotoxins.(10) Thus, we reasoned that Foxp3 could reduce neuropathic pain in a similar manner, as microglia play a critical role in neuropathic pain.",
      "startOffset" : 145,
      "endOffset" : 149
    }, {
      "referenceID" : 22,
      "context" : "To treat patients experiencing neuropathic pain, several kinds of drugs, including non-steroidal anti-inflammatory drugs, ion channel blockers, selective serotonin reuptake inhibitors and opioids, are typically prescribed.(23) When these drugs are ineffective, additional therapies, including nerve block, spinal cord stimulation, and deep brain stimulation, are also typically applied to mitigate pain.",
      "startOffset" : 222,
      "endOffset" : 226
    }, {
      "referenceID" : 23,
      "context" : "When these drugs are ineffective, additional therapies, including nerve block, spinal cord stimulation, and deep brain stimulation, are also typically applied to mitigate pain.(24,25) These approaches are limited, however, due to the different etiologies of neuropathic pain.",
      "startOffset" : 176,
      "endOffset" : 183
    }, {
      "referenceID" : 24,
      "context" : "When these drugs are ineffective, additional therapies, including nerve block, spinal cord stimulation, and deep brain stimulation, are also typically applied to mitigate pain.(24,25) These approaches are limited, however, due to the different etiologies of neuropathic pain.",
      "startOffset" : 176,
      "endOffset" : 183
    }, {
      "referenceID" : 25,
      "context" : "These approaches are limited, however, due to the different etiologies of neuropathic pain.(26) Therefore, new analgesics based on knowledge of the biological mechanisms of pain are necessary to overcome these limitations.",
      "startOffset" : 91,
      "endOffset" : 95
    }, {
      "referenceID" : 26,
      "context" : "Microglial inactivators, such as minocycline, pentoxifylline and ibudilast, apparently attenuate neuropathic pain.(27) Unfortunately, due to their short half-life, these compounds only provide analgesia for a limited time.",
      "startOffset" : 114,
      "endOffset" : 118
    }, {
      "referenceID" : 27,
      "context" : "Unfortunately, due to their short half-life, these compounds only provide analgesia for a limited time.(28) To address this problem, some neuroscientists have shifted their focus from chemical inhibitors to neuropathic painrelated genes, because the analgesic effect of gene therapy is proving to be much more persistent than that of chemical therapy.",
      "startOffset" : 103,
      "endOffset" : 107
    }, {
      "referenceID" : 12,
      "context" : "Consequently, mechanical allodynia was significantly reduced for 5 days by the silencing of the p38 gene and subsequent downregulation of spinal microglial activity.(13) In the present study, we attempted to enhance the symptoms of neuropathic pain by decreasing microglial activity via upregulation of the Foxp3 gene, an anti-inflammatory factor in the microglia.",
      "startOffset" : 165,
      "endOffset" : 169
    }, {
      "referenceID" : 28,
      "context" : "Foxp3 was initially identified as a specific marker for CD4 and CD25 Treg cells, and was later found in other cells, including microglia.(29) Interestingly, upregulation of Foxp3 reduced neuronal death in the hippocampus by attenuating neuroinflammation and modulating the expression of inflammatory genes, such as Arg1 and iNOS, in a kainic-induced mouse model of neurodegeneration.",
      "startOffset" : 137,
      "endOffset" : 141
    }, {
      "referenceID" : 9,
      "context" : "Interestingly, upregulation of Foxp3 reduced neuronal death in the hippocampus by attenuating neuroinflammation and modulating the expression of inflammatory genes, such as Arg1 and iNOS, in a kainic-induced mouse model of neurodegeneration.(10) Thus, to investigate whether Foxp3 could similarly attenuate neuropathic pain owing to its anti-inflammatory effect on microglia, we introduced pFoxp3 into the spinal microglia of SNL-induced rats with the aid of pFoxp3-encapsulated PLGA NPs.",
      "startOffset" : 241,
      "endOffset" : 245
    }, {
      "referenceID" : 29,
      "context" : "These findings are consistent with previous studies demonstrating suppression of microglial activity via anti-inflammatory genes, such as IL-10, thereby ameliorating pain behavior by tuning neuroinflammatory genes that are pro- or anti-nociceptive.(30) In this study, the PLGA co-polymer was employed in several ways in vivo to deliver pFoxp3.",
      "startOffset" : 248,
      "endOffset" : 252
    }, {
      "referenceID" : 11,
      "context" : "The PLGA co-polymer is a wellknown, safe and biodegradable biomaterial approved by the US FDA.(12) Furthermore, the prepared PLGA NPs (224 nm in diameter) were large enough to enclose most of the plasmid (100 μg per 25 mg PLGA), while also readily endocytosing into the microglia.",
      "startOffset" : 94,
      "endOffset" : 98
    } ],
    "year" : 2019,
    "abstractText" : "Microglia play a critical role in neuropathic pain. Since upregulated Foxp3 in microglia enhances tissue repair by resolving neuroinflammation in excitotoxin-induced neuronal death, it may attenuate neuropathic pain in a similar manner. Therefore, this study tests whether Foxp3 introduced with poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles (Foxp3 NPs) can alleviate neuropathic pain by inhibiting microglia activity. The prepared Foxp3 NPs had an anti-inflammatory effect on lipopolysaccharide-stimulated BV2 cells in vitro, and localized to spinal microglia in vivo. Further, the Foxp3 NPs significantly attenuated pain behavior induced by spinal nerve ligation in rats for 7 days by suppressing microglial activity, followed by the downregulation of pro-nociceptive genes and the upregulation of antinociceptive genes in the spinal dorsal horn. Collectively, these data suggest that Foxp3 NPs effectively relieve neuropathic pain in animals by reducing microglia activity and subsequent modulation of neuroinflammation, and may be of therapeutic value in the treatment of neuropathic pain. © 2019 Elsevier Inc. All rights reserved.",
    "creator" : "Elsevier"
  }
}